IMU (ASX) Media Thread

Originally posted by Jov88: ↑

In London so bit behind, but have read all comments and watched the video. Couldn't have asked for more based on cohorts. Suffice it to say, CF33 works! Would have liked to see the imaging especially on intravenous, based on Leslies comments, higher doses might be the ticket to see desired effecacy. Ultimately, we know IT works very well because the the virus is able to replicate faster than the injected tumour and keep doing so until it bursts and pours out a high amount of virus to go and destroy other tumours. It's a non linear situation we are likely to experience, I think they why it's so important to continue getting data. If the patients immunity is shot, less of a response but less CF33 cleared so more replication but less immune response, also the lymphatic system is also unique in terms of spread depending on cancer so how far the virus needs to travel to get to metastisasis isn't constant.

I am very happy overall, and explains why IMU have bought Azer Cell, they are confident CF33 work-s! Still not certain of TCell exhaustion which is an issue with many CAR Ts but a lot of new data is out of how to curb that. Ultimately, IMU has a therapy that can find and infultrate cancer. We know this because the patient with a complete response had malignant tumours but were injected direct into tumours. We know it kills tumours also, givrnthe complete response. We also know (and this is a big one) safety is high and toxicity is low so little patient burden, what a relief for those patients! OnCARlytics is looking amazing right now…

Also, I bumped this post to show some of the comparative data for therapies that are getting bought out for billions. Keep in mind which data is for solid tumours and which for blood and you'll see what's highly sort after even with horrible sides…we are looking good, just a matter of time.

Cheers.

Ps: thanks for every ones analysis, super helpful.

Expand

Re T Cell exhaustion strategy:

Clinical Oncology Journal Author Oncologist Steven Albelda :"An alternative strategy focused on administering multiple doses of short-lived CAR T cells in an attempt to pre-empt exhaustion and maintain a functional effector pool".
Originally posted by Jov88

Originally posted by Jov88: ↑

In London so bit behind, but have read all comments and watched the video. Couldn't have asked for more based on cohorts. Suffice it to say, CF33 works! Would have liked to see the imaging especially on intravenous, based on Leslies comments, higher doses might be the ticket to see desired effecacy. Ultimately, we know IT works very well because the the virus is able to replicate faster than the injected tumour and keep doing so until it bursts and pours out a high amount of virus to go and destroy other tumours. It's a non linear situation we are likely to experience, I think they why it's so important to continue getting data. If the patients immunity is shot, less of a response but less CF33 cleared so more replication but less immune response, also the lymphatic system is also unique in terms of spread depending on cancer so how far the virus needs to travel to get to metastisasis isn't constant.

I am very happy overall, and explains why IMU have bought Azer Cell, they are confident CF33 work-s! Still not certain of TCell exhaustion which is an issue with many CAR Ts but a lot of new data is out of how to curb that. Ultimately, IMU has a therapy that can find and infultrate cancer. We know this because the patient with a complete response had malignant tumours but were injected direct into tumours. We know it kills tumours also, givrnthe complete response. We also know (and this is a big one) safety is high and toxicity is low so little patient burden, what a relief for those patients! OnCARlytics is looking amazing right now…

Also, I bumped this post to show some of the comparative data for therapies that are getting bought out for billions. Keep in mind which data is for solid tumours and which for blood and you'll see what's highly sort after even with horrible sides…we are looking good, just a matter of time.

Cheers.

Ps: thanks for every ones analysis, super helpful.

Expand

No.	Vol.	Price($)
7	1082545	5.5¢

No.

Vol.

Price($)

1082545

5.5¢

Price($)	Vol.	No.
5.7¢	603058	6

Price($)

Vol.

No.

5.7¢

603058

No.	Vol.	Price($)
4	341818	0.055
9	509187	0.054
14	1776123	0.053
22	1646348	0.052
16	4794350	0.051

No.

Vol.

Price($)

341818

0.055

509187

0.054

1776123

0.053

1646348

0.052

4794350

0.051

Price($)	Vol.	No.
0.057	603058	6
0.058	1006279	6
0.059	21714	1
0.060	1512398	12
0.061	1091000	7

Price($)

Vol.

No.

0.057

603058

0.058

1006279

0.059

21714

0.060

1512398

0.061

1091000

(20min delay)
Last 5.7¢		Change 0.001(1.79%)		Mkt cap ! $418.9M

Open	High	Low	Value	Volume
5.6¢	5.7¢	5.4¢	$461.9K	8.347M

Media Thread, page-10529

Flynn Gold flags mid-grade drill hits and always eye-catching rock chips

Warren Tredrea’s weekly sports business wrap: the latest on business in sport

Lake Resources implies news article on job cuts made up; non-core sales "not material" and no rule 15.7 breach

AI stocks: What to expect in 2024-25

Wealth Within considers potential takeover targets in Australia's booming infrastructure industry

Talking Australia's very competitive property landscape: Realty Talks

Week 29 Wrap: Trump in spotlight again; China's Third Plenum a yawnfest; RBA's August move a mystery

NSW approves J-POWER's $380M buyout of Genex Power, giving it ownership of QLD net zero project

Imricor raises $35M to pursue growth and expansion into Australia and NZ

Metalicity looking for offers on Admiral Bay zinc project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Media Thread, page-10529

Top Stories

Flynn Gold flags mid-grade drill hits and always eye-catching rock chips

Warren Tredrea’s weekly sports business wrap: the latest on business in sport

Lake Resources implies news article on job cuts made up; non-core sales "not material" and no rule 15.7 breach

AI stocks: What to expect in 2024-25

Wealth Within considers potential takeover targets in Australia's booming infrastructure industry

Talking Australia's very competitive property landscape: Realty Talks

Week 29 Wrap: Trump in spotlight again; China's Third Plenum a yawnfest; RBA's August move a mystery

NSW approves J-POWER's $380M buyout of Genex Power, giving it ownership of QLD net zero project

Imricor raises $35M to pursue growth and expansion into Australia and NZ

Metalicity looking for offers on Admiral Bay zinc project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News